Hikma injectables business could be worth $2.2bn
This article was originally published in Scrip
When Hikma Pharmaceuticals announced on Friday that it was considering "strategic options" for its injectables business after receiving a number of unsolicited expressions of interest, the London-listed Jordanian pharma group saw its shares shoot up 8% to £9.37.
You may also be interested in...
BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.
Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.
Infographic: Scrip homes in on key figures for companies integrating major acquisitions or divesting significant parts of their business.